glp 1 agonists approved for weight loss Is GLP-1 Safe Loss? Peptides, Benefits & Risks List of approved and pending
Description
Zheng, L., et al
This therapeutic was introduced in the United States in 2012
Secondary outcomes included nonfatal MI, nonfatal stroke, HHF and renal composite outcome, defined in most trials as a composite of progression to end-stage renal disease or a sustained decrease of at least 40% in estimated glomerular filtration rate (eGFR)
Annual Review of Nutrition , 29, 2141
XiaoTian L, QiNan W, XiaGuang G, WuQuan D, Bing C, ZiWen L
